Localised heating of tumours utilising injectable magnetic nanoparticles for hyperthermia cancer therapy.
This study reports an investigation of hyperthermia cancer therapy utilising an alternating magnetic field to induce a localised temperature increase on tumours by using injectable magnetic nanoparticles. In-vitro and in-vivo experiments represent the feasibility of hyperthermia cancer therapy. A feedback temperature control system was first developed to keep the nanoparticles at a constant temperature to prevent overheating in the tumours such that a safer and more precise cancer therapy becomes feasible. By using the feedback temperature control system, magnetic nanoparticles can be heated up to the specific constant temperatures, 37, 40, 42, 45, 46 and 47 degrees C, respectively, with a variation less than 0.2 degrees C. With this approach, the in-vitro survival rate of tumour cells at different temperatures can be systematically explored. It was experimentally found that the survival rate of cancer cells can be greatly reduced while CT-26 cancer cells were heated above 45 degrees C. Besides, localised temperatures increase as high as 59.5 degrees C can be successfully generated in rat livers by using the proposed method. Finally, complete regression of tumour was achieved. The developed method used injectable magnetic nanoparticles and may provide a promising approach for hyperthermia cancer therapy.
Tseng
H-Y
HY
National Cheng Kung University, Department of Engineering Science, Tainan, Taiwan.
Lee
G-B
GB
Lee
C-Y
CY
Shih
Y-H
YH
Lin
X-Z
XZ
D000818:Animals; D045744:Cell Line, Tumor; D002470:Cell Survival; D003110:Colonic Neoplasms / Q000473:pathology / Q000628:therapy*; D003911:Dextrans; D004867:Equipment Design; D019544:Equipment Failure Analysis; D052203:Ferrosoferric Oxide; D006979:Hyperthermia, Induced / Q000295:instrumentation* / Q000379:methods; D007267:Injections; D007501:Iron / Q000008:administration & dosage*; D008099:Liver / Q000473:pathology; D008280:Magnetics / Q000295:instrumentation*; D058185:Magnetite Nanoparticles; D051379:Mice; D008807:Mice, Inbred BALB C; D053758:Nanoparticles / Q000627:therapeutic use*; D036103:Nanotechnology / Q000295:instrumentation* / Q000379:methods; D010087:Oxides / Q000008:administration & dosage*; D051381:Rats
D003911:Dextrans; D058185:Magnetite Nanoparticles; D010087:Oxides; D007501:Iron; C065507:ferumoxides; D052203:Ferrosoferric Oxide